We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.

Rare Diseases

The National Clinical Programme for Rare Diseases was established on the 2nd December 2013, as a joint iniatitive between the Clinical Strategy and Programmes Division within HSE and the Royal College of Physicians of Ireland.

Programme Objectives and Scope

A ‘rare disease’ is defined in Europe as a life-threatening or chronically debilitating disease affecting no more than 5 people per 10,000. There are an estimated 6-8,000 known rare diseases affecting up to 6% of the total EU population, (at least 30 million Europeans), and perhaps up to 300,000 Irish people during their lives.

Conditions such as Cystic Fibrosis, Haemophilia and PKU are familiar to many. There are many other rare and ultra-rare conditions. The biggest bulk, however, of the presenting conditions are accounted for by about 350 conditions. Approximately 80% of these conditions are genetic and although a high proportion present in childhood, many also present for the first time in adulthood.

In Europe, it is recognised that accurate and timely diagnosis and access to treatment for individuals with rare diseases are severely hampered by a few major issues. These include lack of recognition and visibility in health care systems leading to difficulties in coordination and communication, the lack of national policies with limited and fragmented resources for individuals with rare diseases, with often the lack of specific clinical expertise for the condition in the specific country, and very highly fragmented clinical research leading to inefficient use of limited resources.

The primary concerns expressed by patients, families and the medical professionals are the prolonged and difficult diagnostic journey and the lack of information and lack of awareness of rare diseases in the community. These difficulties were reflected in the on line public consultation, ‘Have your say’ (HSE 2012).

The programme's objectives are as follows:

Access

Patients with rare diseases and their families should have access to quality information and support, to enable accurate and timely diagnosis and access to appropriate specialist care.

Quality

Clinical expertise for rare diseases should be provided through a network of national Centres of Excellence/Health Care Providers or at designated centres abroad.

Value

Timely access to appropriate diagnosis and care should result in decreased mortality, morbidity and disability and be cost-effective.

 

The scope of the National Clinical Programme for Rare Diseases includes the following disease categories:

  • Single gene disorders
  • Chromosomal disorders
  • Hereditary metabolic disorders
  • Haemophilia and hereditary coagulation disorders
  • Rare congenital disorders
  • Rare endocrine disorders
  • Neurological disorders and neuro-metabolic disorders
  • Rare skin disorders
  • Rare kidney diseases
  • Rare eye disease
  • Rare connective tissue/skeletal/autoimmune disorders
  • Rare lung disorders including alpha-1-antitrypsin disorder and excluding Cystic Fibrosis

Please note that rare cancers come under the National Cancer Control Programme and Cystic Fibrosis under the National Clinical Programme for Cystic Fibrosis.

Clinical Strategy and Programmes Division